164 related articles for article (PubMed ID: 2009918)
1. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL
Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
3. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13.
Lebel-Binay S; Laguerre B; Quintin-Colonna F; Conjeaud H; Magazin M; Miloux B; Pecceu F; Caput D; Ferrara P; Fradelizi D
Eur J Immunol; 1995 Aug; 25(8):2340-8. PubMed ID: 7664796
[TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
5. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
Miki S; Ksander B; Streilein JW
Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
7. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
8. Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity.
Mills GB; Carlson G; Paetkau V
J Immunol; 1980 Nov; 125(5):1904-9. PubMed ID: 6968766
[TBL] [Abstract][Full Text] [Related]
9. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
10. IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL.
Levraud JP; Duffour MT; Cordier L; Perricaudet M; Haddada H; Kourilsky P
J Immunol; 1997 Apr; 158(7):3335-43. PubMed ID: 9120291
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
12. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.
Olver S; Groves P; Buttigieg K; Morris ES; Janas ML; Kelso A; Kienzle N
Cancer Res; 2006 Jan; 66(1):571-80. PubMed ID: 16397274
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
[TBL] [Abstract][Full Text] [Related]
14. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of anti-Pichinde virus cytotoxic T cell memory by cyclophosphamide and restoration by coinfection or interleukin 2.
Walker CM; Paetkau V; Rawls WE; Rosenthal KL
J Immunol; 1985 Aug; 135(2):1401-7. PubMed ID: 2989365
[TBL] [Abstract][Full Text] [Related]
16. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.
Yang G; Hellström KE; Mizuno MT; Chen L
J Immunol; 1995 Oct; 155(8):3897-903. PubMed ID: 7561096
[TBL] [Abstract][Full Text] [Related]
17. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
[TBL] [Abstract][Full Text] [Related]
18. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
20. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
Ksander BR; Streilein JW
J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
